Mga Batayang Estadistika
| CIK | 1929281 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioLife Sciences Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| October 20, 2023 |
BLFE / Biolife Sciences Inc / Mango Innovation LLC - SC 13G Passive Investment SC 13G 1 mangosc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BioLIfe Sciences Inc (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09076L103 (CUSIP Number) October 17, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| April 6, 2023 |
BIOLIFE SCIENCES INC. 8,400,000,000 Shares of Common Stock Filed Pursuant to Rule 253(g)(1) File No. 024-11898 OFFERING CIRCULAR BIOLIFE SCIENCES INC. 8,400,000,000 Shares of Common Stock This Post-Qualification Offering Circular Amendment No. 4 (the “PQA4”) amends the Offering Statement of BioLife Sciences, Inc., a Florida corporation, qualified on June 30, 2022, Post-Qualification Offering Circular Amendment No. 1 dated December 23, 2022, as qualified o |
|
| March 30, 2023 |
BIOLIFE SCIENCES INC. 8,400,000,000 Shares of Common Stock Post-Qualification Amendment No. 4 File No. 024-11898 OFFERING CIRCULAR BIOLIFE SCIENCES INC. 8,400,000,000 Shares of Common Stock This Post-Qualification Offering Circular Amendment No. 4 (the “ PQA4” ) amends the Offering Statement of BioLife Sciences, Inc., a Florida corporation, qualified on June 30, 2022, Post-Qualification Offering Circular Amendment No. 1 dated December 23, 2022, as qualifi |
|
| March 30, 2023 |
EXHIBIT 12.1 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 940-367-6154 March 29, 2023 BioLife Sciences, Inc. 2831 St. Rose Parkway #200, Henderson, Nevada 89052 Re: Offering Statement on Form 1-A Gentlemen: We have been requested by BioLife Sciences, Inc., a Florida corporation (the “Company”), to furnish you with our opinion as to the matters hereinafter |
|
| February 22, 2023 |
Filed Pursuant to Rule 253(g)(2) File No. 024-11898 Offering Circular Supplement No. 1 Dated February 22, 2023 BIOLIFE SCIENCES, INC. 6,400,000,000 Shares of Common Stock An Offering Statement (the “Offering Statement”) pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission (“SEC”). The Offering Statement was Qualified on June 30, 2022. Pos |
|
| February 21, 2023 |
BIOLIFE SCIENCES INC. 6,400,000,000 Shares of Common Stock Filed Pursuant to Rule 253(g)(1) File No. 024-11898 OFFERING CIRCULAR BIOLIFE SCIENCES INC. 6,400,000,000 Shares of Common Stock This Post-Qualification Offering Circular Amendment No. 2 (the “PQA2”) amends the Offering Statement of BioLife Sciences, Inc., a Florida corporation, qualified on June 30, 2022, and Post-Qualification Offering Circular Amendment No. 1 dated December 23, 2022, as qualifi |
|
| February 17, 2023 |
Post-Qualification Amendment No. 3 File No. 024-11898 EXPLANATORY NOTE The sole purpose of this Post-Qualification Amendment No. 3 is to amend the exhibit index and to submit Exhibit 12.1, to correct certain scrivener’s errors that were included in Exhibit 12.1 to Post-Qualification Amendment No. 2. Accordingly, this Post-Qualification Amendment No. 3 consists only of Part I, this Explanatory Note |
|
| February 17, 2023 |
EXHIBIT 12.1 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 940-367-6154 February 17, 2023 BioLife Sciences, Inc. 2831 St. Rose Parkway #200 Henderson, Nevada 89052 Re: Offering Statement on Form 1-A Gentlemen: We have been requested by BioLife Sciences, Inc., a Florida corporation (the “Company”), to furnish you with our opinion as to the matters hereinafte |
|
| February 17, 2023 |
BioLife Sciences, Inc. 2831 Saint Rose Parkway, Suite 200 Henderson, Nevada 89052 BioLife Sciences, Inc. 2831 Saint Rose Parkway, Suite 200 Henderson, Nevada 89052 February 17, 2023 VIA EDGAR Daniel Crawford Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: BioLife Sciences, Inc. (the “Company”) Post-qualification Amendment No. 2 to Offering Statement on Form 1-A Filed February 9, 2023 and Po |
|
| February 9, 2023 |
BIOLIFE SCIENCES INC. 6,400,000,000 Shares of Common Stock PART II AND III 2 blfe1aa.htm 1-A POS Post-Qualification Amendment No. 2 File No. 024-11898 OFFERING CIRCULAR BIOLIFE SCIENCES INC. 6,400,000,000 Shares of Common Stock This Post-Qualification Offering Circular Amendment No. 2 (the “PQA2”) amends the Offering Statement of BioLife Sciences, Inc., a Florida corporation, qualified on June 30, 2022, and Post-Qualification Offering Circular Amendment N |
|
| February 9, 2023 |
EXHIBIT 12.1 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 940-367-6154 February 9, 2022 BioLife Sciences, Inc. 2831 St. Rose Parkway #200, Henderson, Nevada 89052 Re: Offering Statement on Form 1-A Gentlemen: We have been requested by BioLife Sciences, Inc., a Florida corporation (the “Company”), to furnish you with our opinion as to the matters hereinafte |
|
| January 20, 2023 |
Offering Circular Supplement Dated January 20, 2023 253G2 1 blfe253g2.htm 253G2 Filed Pursuant to Rule 253(g)(2) File No. 024-11898 Offering Circular Supplement Dated January 20, 2023 A Post-Qualification Amendment No. 1 to an Offering Statement (the “PQA”) pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission (“SEC”). The PQA was Qualified on December 29, 2022. This Offering Circular Suppl |
|
| January 4, 2023 |
BIOLIFE SCIENCES INC. 1,400,000,000 Shares of Common Stock 253G1 1 blfe1aa.htm 253G1 Filed Pursuant to Rule 253(g)(1) File No. 024-11898 OFFERING CIRCULAR BIOLIFE SCIENCES INC. 1,400,000,000 Shares of Common Stock This Post-Qualification Offering Circular Amendment No. 1 (the “PQA”) amends the Offering Statement of BioLife Sciences, Inc., a Florida corporation, qualified on November 25, 2021, and as amended on November 10, 2022, and qualified on June 30, |
|
| December 23, 2022 |
EX1A-2A CHARTER 3 blfeex22.htm ARTICLES OF CONVERSION EXHIBIT 2.2 1 2 3 4 5 |
|
| December 23, 2022 |
BIOLIFE SCIENCES INC. 1,400,000,000 Shares of Common Stock PART II AND III 2 blfe1aa.htm 1-A POS Post-Qualification Amendment No. 1 File No. 024-11898 OFFERING CIRCULAR BIOLIFE SCIENCES INC. 1,400,000,000 Shares of Common Stock This Post-Qualification Offering Circular Amendment No. 1 (the “PQA”) amends the Offering Statement of BioLife Sciences, Inc., a Florida corporation, qualified on November 25, 2021, and as amended on November 10, 2022, and qualifie |
|
| December 23, 2022 |
EXHIBIT 12.1 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 940-367-6154 December 23, 2022 BioLife Sciences, Inc. 2831 St. Rose Parkway #200, Henderson, Nevada 89052 Re: Offering Statement on Form 1-A Gentlemen: We have been requested by BioLife Sciences, Inc., a Florida corporation (the “Company”), to furnish you with our opinion as to the matters hereinaft |
|
| December 23, 2022 |
EXHIBIT 2.3 1 2 3 4 5 6 |
|
| December 9, 2022 |
1-A-W 1 p129221f1aw.htm December 9, 2022 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Biolife Sciences Inc. Request for Withdrawal of Amendment to Offering Statement on Form 1-A filed under form type 1-A/A (File No. 024-10565) Ladies and Gentlemen: On behalf of Biolife Sciences Inc. (the “Company”), we hereby submit this letter to notify the Secur |
|
| November 29, 2022 |
EX1A-2A CHARTER 3 ex1a-21.htm EXHIBIT 1A-2A EXHIBIT 2.1 |
|
| November 29, 2022 |
EXHIBIT 12.1 Jonathan D. Leinwand, P.A. 18305 Biscayne Blvd. Suite 200 Aventura, FL 33160 Tel: (954) 903-7856 Fax: (954) 252-4265 E-mail: [email protected] May 27, 2022 Board of Directors BioLife Sciences Inc. 2831 St. Rose Parkway #200 Henderson, NV 89052 Ladies and Gentlemen: We are acting as counsel to BioLife Sciences Inc., a Nevada corporation (“BL”), for the purpose of rendering an opinion |
|
| November 29, 2022 |
BIOLIFE SCIENCES INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS EXHIBIT 4.1 BIOLIFE SCIENCES INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID |
|
| November 29, 2022 |
File No. As filed with the Securities and Exchange Commission on May 31, 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Subject to Completion. Preliminary Offering Circular dated May 27, 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”). Information contained in this Prelim |
|
| November 29, 2022 |
EXHIBIT 6.1 January 31st, 2022 Health Box LLC 1901 Johnson Avenue, #669 Kingman, Arizona, 86402 & Bio Life Sciences Inc. 2831 Saint Rose Parkway Suite 200, Henderson, NV, 89052 Re: Agreement to Purchase the Capital Stock of Health Box LLC This agreement (the "Agreement") summarizes the principal terms of the agreement considered by BioLife Sciences Inc. ("Buyer") regarding its acquisition of all o |
|
| July 14, 2022 |
Filed Pursuant to Rule 253(g)(2) File No. 024-11898 As filed with the Securities and Exchange Commission on July 14, 2022 OFFERING CIRCULAR BIOLIFE SCIENCES INC. 2831 St. Rose Parkway #200, Henderson, NV, USA 89052 +1833-919-1037 Offering Total: $20,000,000 Up to 400,000,000 Shares of Common Stock Offering Price $.05 per Share Maximum Offering of $20,000,000 By this Offering Circular, BioLife Scie |
|
| June 28, 2022 |
June 28, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attn: Jason Drory 100 F Steet, N. |
|
| June 28, 2022 |
June 28, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attn: Jason Drory 100 F Steet, N. |
|
| May 31, 2022 |
EX1A-6 MAT CTRCT.1 5 blfeex61.htm PURCHASE AGREEMENT EXHIBIT 6.1 January 31st, 2022 Health Box LLC 1901 Johnson Avenue, #669 Kingman, Arizona, 86402 & Bio Life Sciences Inc. 2831 Saint Rose Parkway Suite 200, Henderson, NV, 89052 Re: Agreement to Purchase the Capital Stock of Health Box LLC This agreement (the "Agreement") summarizes the principal terms of the agreement considered by BioLife Scien |
|
| May 31, 2022 |
EXHIBIT 2.1 |
|
| May 31, 2022 |
PART II AND III 2 blfe1a.htm FORM 1-A File No. As filed with the Securities and Exchange Commission on May 31, 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Subject to Completion. Preliminary Offering Circular dated May 27, 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”) |
|
| May 31, 2022 |
EX1A-12 OPN CNSL.1 6 blfeex121.htm OPINION EXHIBIT 12.1 Jonathan D. Leinwand, P.A. 18305 Biscayne Blvd. Suite 200 Aventura, FL 33160 Tel: (954) 903-7856 Fax: (954) 252-4265 E-mail: [email protected] May 27, 2022 Board of Directors BioLife Sciences Inc. 2831 St. Rose Parkway #200 Henderson, NV 89052 Ladies and Gentlemen: We are acting as counsel to BioLife Sciences Inc., a Nevada corporation (“BL” |
|
| May 31, 2022 |
BIOLIFE SCIENCES INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS EX1A-4 SUBS AGMT.1 4 blfeex41.htm SUBSCRIPTION AGREEMENT EXHIBIT 4.1 BIOLIFE SCIENCES INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTME |
